Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. - Wikidata - awgldk - TriplyDB

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.

http://www.wikidata.org/entity/Q41846059

about

Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis Knocking down disease: a progress report on siRNA therapeutics Liver-targeted gene therapy: Approaches and challenges Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective.The notorious R.N.A. in the spotlight - drug or target for the treatment of disease Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells.Identification of siRNA delivery enhancers by a chemical library screen.Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers.Enteral siRNA delivery technique for therapeutic gene silencing in the liver via the lymphatic route Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing The delivery of therapeutic oligonucleotides Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk Development of Antisense Drugs for Dyslipidemia.Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics.Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs.Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides.Chylomicronaemia--current diagnosis and future therapies.Oligonucleotide therapeutics: chemistry, delivery and clinical progress.Locked nucleic acid (LNA): Based single-stranded oligonucleotides are not genotoxic.Cellular environment-responsive nanomaterials for use in gene and siRNA delivery: molecular design for biomembrane destabilization and intracellular collapse.Gene editing technology as an approach to the treatment of liver diseases.Concise postsynthetic preparation of oligonucleotide-oligopeptide conjugates through facile disulfide bond formation.Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.The chemical evolution of oligonucleotide therapies of clinical utility.Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy.Down-regulation of the liver-derived plasma protein fetuin-B mediates reversible female infertility.Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention.Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys.Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA To Wnt or Lose: The Missing Non-Coding Linc in Colorectal Cancer.Synthesis of dinucleoside acylphosphonites by phosphonodiamidite chemistry and investigation of phosphorus epimerization.Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol.Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates.Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay.

P2860

Q26782089-56CF57DB-C6BF-4DF5-86AF-F0DAC61A2224 Q28082939-0DBD3E08-6C18-4FBF-9EFD-136DA42B9823 Q28085748-4E3DD3A9-8ABA-4CCC-B6E5-5A1B3471321F Q33418637-DF4F11A9-33E7-4B21-9D64-C047F8757DD9 Q33739733-820933FC-3CFE-4843-84AF-AB786497E9FC Q35098066-6E8B7AED-072B-4058-AE99-03883F17E3A1 Q35721260-FBC595A2-3DCE-40F3-BDA6-342EC747160A Q36228096-57D67B74-B3B0-4EDE-B513-F3B097287D13 Q36305841-D836D9E7-6522-4184-A551-0A075AA6E902 Q36410111-8D5B91AD-314C-4A04-B9B9-E76C4DC3689F Q36617508-EEAEB3F2-01CF-4C52-97FF-C2B396DDC125 Q37031903-10AAEE9A-6AC7-437E-A5BE-73029E5F292A Q37210936-E2096B7D-0C9F-4164-A650-6F8CC5DB6C28 Q37238891-2B645575-1E22-4A53-802C-20ACD3305373 Q37334501-0AAAE6EE-FD12-47B6-971A-F8821264851C Q37387192-EE2AE666-7AAF-465F-B4FF-C5265F769F70 Q37718173-16E265EB-3CC1-4A6C-BC94-9557BF041F96 Q38289176-A0E90174-635D-4D84-A533-0B49244902DE Q38289648-23FD7B44-4E67-4070-80A7-03D8CC0BDE69 Q38291806-30790CD9-2A6E-4F94-9057-E0F9DC476A07 Q38366873-D0098EFD-9987-4A64-87A3-07DA629C3226 Q38618638-0E7D8225-69E5-46E2-A077-A3CB5060D880 Q38712204-C2E523DD-B767-4544-9D41-7BD61B4F1A5A Q38733888-46A692E4-DD53-46BC-A478-CAD36F027B40 Q38749884-341751F8-6C0F-4557-9558-8DFA6E14B5A9 Q38834667-81486DC1-7F85-46C3-AAEB-ABD6F2E5DFF8 Q38985774-CDDDF78C-50F4-46BE-B4F9-923D21089AA5 Q39154511-8A933481-6E58-44C3-A058-76296D4A05E3 Q39175404-E9D9A5B5-E261-4D87-B21C-96C478A8B8F2 Q39298143-7D017A8E-F46D-4FAC-BCF5-4A46896E872C Q40482454-2AFBFBBF-7ADB-4F06-862B-145F05C98E2C Q41035651-D32BF296-C9BC-4376-86CD-FA6A38B7A174 Q41517624-CA69A5E7-9189-4667-BCAC-D0A5AA7A6712 Q41520047-2B0BBDD6-CEFA-4766-8EC8-CFAD8C8FAA8B Q41660291-E4E2A0C0-8663-44D1-969A-2D3D709F659F Q42117035-FA3198A6-6DEC-4C6B-B546-E7747A1BD766 Q43168929-78A50D27-B925-41B1-9A4C-3454E03A3F2E Q47120143-82519CFF-DF02-4013-BBA3-7C90E3FBDAA8 Q47363697-89AA5935-092A-4D19-9C5F-3CC11996B080 Q47815341-59EEB5E0-89BA-4E05-9241-4351C5FEA3E1

P2860

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.

http://www.wikidata.org/entity/Q41846059

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Targeted delivery of antisense ...... roves potency 10-fold in mice.

@en

type

label

Targeted delivery of antisense ...... roves potency 10-fold in mice.

@en

prefLabel

Targeted delivery of antisense ...... roves potency 10-fold in mice.

@en

P1433

Q41846059-E876203F-CE95-4CE9-9F1C-28468E17BA1E

P1476

Q41846059-27B21060-4031-494B-BE8F-0455780C4863

P2093

Q41846059-07EF60BD-4614-449A-A88B-749599F54460

Q41846059-09B3807A-E2EA-4906-B996-64DD1E910EFA

Q41846059-1030FA58-E7A8-4670-BEEC-94F62FC098DF

Q41846059-1A7FB616-6F96-40C8-B4D3-CC9160E81CAC

Q41846059-1AC46335-FC29-4CC0-BB7E-03C583C78A43

Q41846059-1F0022CD-5844-4ED3-9904-BBF33CBF8A17

Q41846059-5009217E-F874-4F74-B4AE-3CCDE9118ED9

Q41846059-57320CDE-CBE0-4934-A06B-9E9E78A4C9DA

Q41846059-7034CC6A-1E34-4B47-B47C-A59BADBDE369

Q41846059-74654AEE-616B-436D-AEC1-B1D1BC45D068

P2860

Q41846059-108FED6C-ABBB-4FE8-A2E7-7E7EAE82E0A5

Q41846059-11910057-DB60-4A8C-A4D9-D357B42D6C9A

Q41846059-19A9BDE5-FC7F-40ED-9012-0CC78073071D

Q41846059-1D90D66B-7905-4A64-8AEE-468D3953F1F5

Q41846059-26A70C67-84BB-4B0E-BB52-77E9E8D3B541

Q41846059-45C3EACA-63EF-41A4-A992-CD944E1855CC

Q41846059-57D6207F-AF10-4812-8B20-FB506BFFD25D

Q41846059-5F1AE63E-88EB-42AC-9D51-24A8B1C9CD8F

Q41846059-635E2236-7F90-4A15-A534-56F7C959BDE5

Q41846059-6BD875A1-7A29-4DA4-BFF4-3B388B256961

P304

Q41846059-217FDCAF-D506-4631-8FB9-D1CE79E7244E

P31

Q41846059-4430CBFA-E068-4BF5-A363-76BEB17D37DB

P356

Q41846059-97B66758-574D-4D10-898C-5E64498A4C34

P433

Q41846059-807BBF43-5F5A-4C72-93D2-B01D4563FF67

P478

Q41846059-D9BC1FA5-8B14-40DC-85D9-44AC1E9DEBD9

P50

Q41846059-B0BF1FB8-7B6C-4FD8-8EC3-4BC8293DCE38

P577

Q41846059-212D8C81-B49E-4B62-8E3A-C4B46B21CFC5

P5875

Q41846059-0766AA03-26F6-45FB-A540-5288912813BB

P698

Q41846059-CD594B6B-8A41-4C6D-89DB-26EA9989F5B6

P932

Q41846059-76786621-1622-459E-8DCC-9469E1BE55AA

P356

P1433

Nucleic Acids Research

P1476

Targeted delivery of antisense ...... proves potency 10-fold in mice

@en

P2093

Alfred Chappell

http://www.w3.org/2001/XMLSchema#string

Audrey Low

http://www.w3.org/2001/XMLSchema#string

Brett P Monia

http://www.w3.org/2001/XMLSchema#string

Chenguang Zhao

http://www.w3.org/2001/XMLSchema#string

Eric E Swayze

http://www.w3.org/2001/XMLSchema#string

Heather F Murray

http://www.w3.org/2001/XMLSchema#string

Jeff Crosby

http://www.w3.org/2001/XMLSchema#string

Jinghua Yu

http://www.w3.org/2001/XMLSchema#string

Karsten Schmidt

http://www.w3.org/2001/XMLSchema#string

Mariam Aghajan

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA

Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor

Synthesis, Improved Antisense Activity and Structural Rationale for the Divergent RNA Affinities of 3′-Fluoro Hexitol Nucleic Acid (FHNA and Ara-FHNA) Modified Oligonucleotides

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans

Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.

Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor.

Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates

The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2,6-galactose.

P304

8796-8807

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NAR/GKU531

http://www.w3.org/2001/XMLSchema#string

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263746572

http://www.w3.org/2001/XMLSchema#string

P698

24992960

http://www.w3.org/2001/XMLSchema#string

P932

4117763

http://www.w3.org/2001/XMLSchema#string